Musa Pinar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Musa Pinar has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Hamad Dheir
Department of Nephrology, Sakarya University Faculty of Medicine, Sakarya, Türkiye
7 shared publications - Ahmed Cihad Genç
Department of Internal Medicine, Sakarya Eğitim ve Araştırma Hastanesi, Adapazari, Turkey, Turkey (Türkiye)
3 shared publications - Alper Azak
Balikesir Ataturk Research and Education Hospital, Department of Nephrology, University of Health Sciences Türkiye, Turkey
3 shared publications - Aysel Toçoğlu
Department of Internal Medicine, Sakarya Eğitim ve Araştırma Hastanesi, Adapazari, Turkey, Turkey (Türkiye)
3 shared publications - Mahmud Islam
Department of Nephrology, Faculty of Medicine, Sakarya University, Sakarya 54050, Türkiye
3 shared publications - Necattin Firat
Sakarya University, Faculty of Medicine
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by MDPI AG in Preprints.org
Acute Kidney Injury Following Gadolinium-Based Contrast Administration: A Single-Center Retrospective Cohort Study
Background/Objectives: Gadolinium-based contrast agents (GBCA) are widely used in magnetic resonance imaging and are generally considered to have a lower potential for nephrotoxicity compared to iodinated contrast agents. However, the actual prevalence of acute kidney injury (AKI) following the use of GBCA and the risk factors contributing to it remain a subject of debate today. The aim of this study is to determine the incidence of acute kidney injury following gadolinium administration (AKI-FGA) in patients undergoing contrast-enhanced magnetic resonance imaging (MRI) and to evaluate the independent risk factors contributing to it. Methods: The medical records of all patients who underwent contrast-enhanced MRI at our hospital between January 2021 and December 2022 were retrospectively reviewed. The patients’ demographic characteristics and serum creatinine levels before and after the contrast-enhanced MRI examination were evaluated. Contrast-induced acute kidney injury (AKI) was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria as an increase in serum creatinine of ≥0.3 mg/dL within 48 hours following contrast agent administration or a rise to ≥1.5 times the baseline value within 7 days. Patients who met the KDIGO criteria were included in the AKI-FGA group. Results: A total of 503 patients who met the inclusion criteria were enrolled in the study. The mean age of the patients was 60.88 ± 16.83 years, and 60.4% of the patients (n=304) were male. Following GBCA administration, a statistically significant increase in serum urea and creatinine levels and a significant decrease in eGFR were observed (p=0.001). AKI-FGA was detected in 16.5% of the patients (n=83). In the AKI-FGA group, the number of patients with a history of coronary artery disease (CAD), diabetes mellitus (DM), hypertension (HT), and congestive heart failure (CHF) was statistically significantly higher than in the group without AKI-FGA (p<0.05). In the multivariate analysis, each 1-year increase in age increased the risk of AKI-FGA by a factor of 1.03, each 0.1 mg/dL increase in baseline serum creatinine increased it by a factor of approximately 4.96, and the presence of DM and CHF increased it by factors of 2.16 and 2.92, respectively. In contrast, no statistically significant association was found between the development of AKI-FGA and HT or CAD. Conclusions: Our findings demonstrate that acute kidney injury can develop following contrast-enhanced MRI even in patients without a history of kidney disease. In particular, for patients who are elderly or have DM, CHF, or elevated baseline serum creatinine levels, it is clinically important to perform an individualized risk assessment prior to contrast-enhanced MRI and to closely monitor kidney function following the procedure.
- 15 October 2026
- Published by MDPI AG in Preprints.org
Open AccessAcute Kidney Injury Following Gadolinium-Based Contrast Administration: A Single-Center Retrospective Cohort Study
Background/Objectives: Gadolinium-based contrast agents (GBCA) are widely used in magnetic resonance imaging and are generally considered to have a lower potential for nephrotoxicity compared to iodinated contrast agents. However, the actual prevalence of acute kidney injury (AKI) following the use of GBCA and the risk factors contributing to it remain a subject of debate today. The aim of this study is to determine the incidence of acute kidney injury following gadolinium administration (AKI-FGA) in patients undergoing contrast-enhanced magnetic resonance imaging (MRI) and to evaluate the independent risk factors contributing to it. Methods: The medical records of all patients who underwent contrast-enhanced MRI at our hospital between January 2021 and December 2022 were retrospectively reviewed. The patients’ demographic characteristics and serum creatinine levels before and after the contrast-enhanced MRI examination were evaluated. Contrast-induced acute kidney injury (AKI) was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria as an increase in serum creatinine of ≥0.3 mg/dL within 48 hours following contrast agent administration or a rise to ≥1.5 times the baseline value within 7 days. Patients who met the KDIGO criteria were included in the AKI-FGA group. Results: A total of 503 patients who met the inclusion criteria were enrolled in the study. The mean age of the patients was 60.88 ± 16.83 years, and 60.4% of the patients (n=304) were male. Following GBCA administration, a statistically significant increase in serum urea and creatinine levels and a significant decrease in eGFR were observed (p=0.001). AKI-FGA was detected in 16.5% of the patients (n=83). In the AKI-FGA group, the number of patients with a history of coronary artery disease (CAD), diabetes mellitus (DM), hypertension (HT), and congestive heart failure (CHF) was statistically significantly higher than in the group without AKI-FGA (p<0.05). In the multivariate analysis, each 1-year increase in age increased the risk of AKI-FGA by a factor of 1.03, each 0.1 mg/dL increase in baseline serum creatinine increased it by a factor of approximately 4.96, and the presence of DM and CHF increased it by factors of 2.16 and 2.92, respectively. In contrast, no statistically significant association was found between the development of AKI-FGA and HT or CAD. Conclusions: Our findings demonstrate that acute kidney injury can develop following contrast-enhanced MRI even in patients without a history of kidney disease. In particular, for patients who are elderly or have DM, CHF, or elevated baseline serum creatinine levels, it is clinically important to perform an individualized risk assessment prior to contrast-enhanced MRI and to closely monitor kidney function following the procedure.
- Open Access
- 24 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Real-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort
Introduction: Real-world epidemiological and longitudinal outcome data on autosomal dominant polycystic kidney disease (ADPKD) remain limited in underrepresented populations, including Türkiye. We aimed to characterize the epidemiology, regional distribution, and renal outcomes of ADPKD in a large multicenter national cohort. Methods: In this retrospective multicenter study, adult patients with ADPKD were identified across tertiary nephrology centers in six regions of Türkiye (2010–2025). Study-based prevalence was calculated using Turkish Statistical Institute population data. Longitudinal renal outcomes were evaluated using serial eGFR measurements and Cox regression models identified predictors of ≥ 40% eGFR decline. Results: A total of 2361 patients were included (mean age 38.6 ± 14 years; 51.8% female). Median province-level study-based prevalence was 3.86 per 100,000 population (IQR 2.92–5.49), with substantial regional variation, highest in the Black Sea region (13.46 per 100,000). Study-based prevalence increased significantly over time (annual percent change 14.4%; 95% CI 13.1–15.6; p < 0.001). During a median follow-up of 6 years, 23.9% experienced a ≥ 40% eGFR decline and 10.5% progressed to kidney failure (eGFR < 15 ml/min/1.73m2). Median annual eGFR decline was − 3.33 mL/min/1.73 m²/year. In multivariable analysis, age (adjusted HR 1.02; 95% CI 1.00–1.03; p = 0.010) and hypertension (adjusted HR 2.33; 95% CI 1.25–4.32; p = 0.007) were independently associated with renal progression, whereas tolvaptan use was associated with a lower risk of progression (adjusted HR 0.56; 95% CI 0.37–0.85; p = 0.004). The Mayo Imaging Classification remained independently predictive of renal outcomes (p = 0.027). Conclusions: This large real-world multicenter cohort highlights the geographically heterogeneous study-based burden of ADPKD across participating regions of Türkiye. Increasing prevalence over time likely reflects improved disease recognition, whereas the relatively low study-based prevalence suggests persistent under-recognition of ADPKD. These findings provide important longitudinal outcome data from an underrepresented population and support the need for earlier detection and improved risk stratification in ADPKD.
- 24 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessReal-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort
Introduction: Real-world epidemiological and longitudinal outcome data on autosomal dominant polycystic kidney disease (ADPKD) remain limited in underrepresented populations, including Türkiye. We aimed to characterize the epidemiology, regional distribution, and renal outcomes of ADPKD in a large multicenter national cohort. Methods: In this retrospective multicenter study, adult patients with ADPKD were identified across tertiary nephrology centers in six regions of Türkiye (2010–2025). Study-based prevalence was calculated using Turkish Statistical Institute population data. Longitudinal renal outcomes were evaluated using serial eGFR measurements and Cox regression models identified predictors of ≥ 40% eGFR decline. Results: A total of 2361 patients were included (mean age 38.6 ± 14 years; 51.8% female). Median province-level study-based prevalence was 3.86 per 100,000 population (IQR 2.92–5.49), with substantial regional variation, highest in the Black Sea region (13.46 per 100,000). Study-based prevalence increased significantly over time (annual percent change 14.4%; 95% CI 13.1–15.6; p < 0.001). During a median follow-up of 6 years, 23.9% experienced a ≥ 40% eGFR decline and 10.5% progressed to kidney failure (eGFR < 15 ml/min/1.73m2). Median annual eGFR decline was − 3.33 mL/min/1.73 m²/year. In multivariable analysis, age (adjusted HR 1.02; 95% CI 1.00–1.03; p = 0.010) and hypertension (adjusted HR 2.33; 95% CI 1.25–4.32; p = 0.007) were independently associated with renal progression, whereas tolvaptan use was associated with a lower risk of progression (adjusted HR 0.56; 95% CI 0.37–0.85; p = 0.004). The Mayo Imaging Classification remained independently predictive of renal outcomes (p = 0.027). Conclusions: This large real-world multicenter cohort highlights the geographically heterogeneous study-based burden of ADPKD across participating regions of Türkiye. Increasing prevalence over time likely reflects improved disease recognition, whereas the relatively low study-based prevalence suggests persistent under-recognition of ADPKD. These findings provide important longitudinal outcome data from an underrepresented population and support the need for earlier detection and improved risk stratification in ADPKD.
- Open Access
- 22 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4017
Sex Differences in Baseline Characteristics and Long-Term Outcomes of Primary Glomerular Diseases: Insights from the TSN-GOLD Registry
Background: Primary glomerular diseases (PGDs) are a leading cause of end-stage kidney disease (ESKD). While sex differences in chronic kidney disease progression have been reported, their role in PGDs remains unclear. Methods: We analyzed 2081 patients with biopsy-proven PGDs from the Turkish Society of Nephrology Glomerular Diseases Working Group (TSN-GOLD) registry. Baseline demographic, clinical, biochemical, and histopathological characteristics were compared between women and men. Outcomes were assessed as a composite of ESKD or death. Logistic and Cox regression models were applied to identify independent risk factors. Kaplan–Meier analyses evaluated survival differences. Results: At baseline, women and men had similar rates of hypertension (36.8% vs. 34.7%, p = 0.322). Women more frequently presented with leukocyturia (31.7% vs. 17.2%, p < 0.001) and hematuria (57.8% vs. 52.3%, p = 0.016), whereas men had higher proteinuria (5011 ± 4925 vs. 4388 ± 4529 mg/day, p = 0.003) and were more likely to be active smokers (20.7% vs. 7.4%, p < 0.001). Serum albumin (3.3 ± 0.8 vs. 3.2 ± 0.9 g/dL) and eGFR (79.7 ± 44.3 vs. 78.7 ± 45.5 mL/min/1.73 m2) were comparable between sexes (both NS). During a median follow-up of 24 months (IQR 7-60), 431 patients (20.7%) reached the composite outcome of ESKD or death (137 deaths [6.6%], 294 ESKD [14.1%]). In the multivariable Cox regression model, lower baseline eGFR (HR 0.98, 95% CI 0.98–0.98, p < 0.001), lower serum albumin (HR 0.65, 95% CI 0.55–0.77, p < 0.001), higher proteinuria (HR 1.03, 95% CI 1.00–1.05, p = 0.043), and biopsy diagnosis of RPGN (HR 3.78, 95% CI 1.37–10.45, p = 0.010) were independent predictors of poor prognosis. Sex was not an independent predictor of outcome (p = 0.48). Kaplan–Meier analysis demonstrated no significant survival difference between women and men (log-rank p = 0.052). Conclusions: In this nationwide PGD cohort, women and men differed significantly in baseline biochemical and clinical parameters, yet sex was not independently associated with progression to ESKD or death. Instead, disease severity at baseline and histopathological features were the main drivers of prognosis.
- 22 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4017
Open AccessSex Differences in Baseline Characteristics and Long-Term Outcomes of Primary Glomerular Diseases: Insights from the TSN-GOLD Registry
Background: Primary glomerular diseases (PGDs) are a leading cause of end-stage kidney disease (ESKD). While sex differences in chronic kidney disease progression have been reported, their role in PGDs remains unclear. Methods: We analyzed 2081 patients with biopsy-proven PGDs from the Turkish Society of Nephrology Glomerular Diseases Working Group (TSN-GOLD) registry. Baseline demographic, clinical, biochemical, and histopathological characteristics were compared between women and men. Outcomes were assessed as a composite of ESKD or death. Logistic and Cox regression models were applied to identify independent risk factors. Kaplan–Meier analyses evaluated survival differences. Results: At baseline, women and men had similar rates of hypertension (36.8% vs. 34.7%, p = 0.322). Women more frequently presented with leukocyturia (31.7% vs. 17.2%, p < 0.001) and hematuria (57.8% vs. 52.3%, p = 0.016), whereas men had higher proteinuria (5011 ± 4925 vs. 4388 ± 4529 mg/day, p = 0.003) and were more likely to be active smokers (20.7% vs. 7.4%, p < 0.001). Serum albumin (3.3 ± 0.8 vs. 3.2 ± 0.9 g/dL) and eGFR (79.7 ± 44.3 vs. 78.7 ± 45.5 mL/min/1.73 m2) were comparable between sexes (both NS). During a median follow-up of 24 months (IQR 7-60), 431 patients (20.7%) reached the composite outcome of ESKD or death (137 deaths [6.6%], 294 ESKD [14.1%]). In the multivariable Cox regression model, lower baseline eGFR (HR 0.98, 95% CI 0.98–0.98, p < 0.001), lower serum albumin (HR 0.65, 95% CI 0.55–0.77, p < 0.001), higher proteinuria (HR 1.03, 95% CI 1.00–1.05, p = 0.043), and biopsy diagnosis of RPGN (HR 3.78, 95% CI 1.37–10.45, p = 0.010) were independent predictors of poor prognosis. Sex was not an independent predictor of outcome (p = 0.48). Kaplan–Meier analysis demonstrated no significant survival difference between women and men (log-rank p = 0.052). Conclusions: In this nationwide PGD cohort, women and men differed significantly in baseline biochemical and clinical parameters, yet sex was not independently associated with progression to ESKD or death. Instead, disease severity at baseline and histopathological features were the main drivers of prognosis.
- Open Access
- 18 April 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2341787
Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group
Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission. CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.
- 18 April 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2341787
Open AccessImmunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group
Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission. CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.
- 4 September 2023
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
Böbrek nakli hastalarında de novo uzatılmış salımlı takrolimus; Güvenli mi?
- 4 September 2023
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
Böbrek nakli hastalarında de novo uzatılmış salımlı takrolimus; Güvenli mi?
- Open Access
- 15 July 2023
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 363-368
Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease
Amaç: Makrofajlardan salınan interferon-gama indüklenebilir protein-10 (IP-10) tromboz ile ilişkilidir. Bu çalışma, şiddetli COVID-19 nedeniyle takip edilen hastaların biyokimyasal belirteçlerini ve IP-10'un mortaliteyi göstermedeki rolünü araştırmayı amaçladı. Materyal ve Metot: Bu çalışmada üniversite hastanesinin yoğun bakım ünitesinde (YBÜ) takip edilen 88 (Kadın %44,3) ağır hastanın retrospektif verileri değerlendirildi. Demografik ve laboratuvar verileri ile D-dimer, Ferritin, Ürik asit, IP-10 değerleri ve diğer biyokimyasal belirteçlere ilişkin veriler ölen ve yaşayan hastaların dosyalarından elde edildi. Bulgular: Yoğun bakımda takip edilen COVID-19 enfeksiyonlu 88 hastanın yaş ortalaması 70,5 ±10 idi. Hayatta kalan gurupta, lenfosit sayısı 1,3 (1-2,1) K/uL, ferritin 151 (90,7-255), D-dimer 386 (293,5-650), LDH 220 (185-286) iken, ölen hastalarda ise, lenfosit sayısı 0,8 (0,5-1,1), ferritin 624 (296-1254) mcg/L, D-dimer 1280 (871-2245) ug/L, LDH 429.5 (368-560) U/L saptandı. Bu parametrelerde p değeri <0,05 idi. Buna karşılık, hayatta kalmayanlarda serum IP-10 seviyeleri hayatta kalanlar da 21,3 (1,2-31,6) pg/mL iken ölen hastalarda 26,6 (11,4-43,6) pg/mL, p=0,04. Sonuç: Şiddetli COVID-19 hastalarında hayatta kalmayanlar ve hayatta kalanların karşılaştırıldığı bu çalışmada, ferritin, ve D-dimerin mortalite için iyi bir tahmin edici potansiyeli olduğu, IP-10'un ise bir belirleyici olamayacağı bulundu. Objective: Interferon-gamma inducible protein-10 (IP-10) released from macrophages is associated with thrombosis. We aimed to investigate patients' biochemical markers following severe COVID-19, concentrating on the role of IP-10 in mortality. Materials and Methods: In our study, we retrospectively evaluated data from 88 (females, 44.3%) severe patients followed in our university hospital's intensive care unit (ICU). We obtained demographic and laboratory data from our study population's files and electronic records, including D-dimer, ferritin, uric acid, IP-10 values, and other biochemical markers. Results: The mean age of all 88 patients with COVID-19 infection followed in the ICU was 70.5 ±10 years. The median for lymphocyte count was 1.3 (1-2.1) vs 0.8 (0.5-1.1) K/uL, ferritin 151 (90.7-255) vs 624 (296-1254) mcg/L, D-dimer 386 (293.5-650) vs 1280 (871-2245) ug/L, LDH 220 (185-286) vs 429.5 (368-560) U/L with a p-value of <0.05 in survivors vs non-survivors respectively. On the other hand, the level of IP-10 was 21.3 (13.2-31.6) vs 26.6 (11.4-43.6) pg/mL with a p-value of 0.04. Conclusions: In this study, in which non-survivors and survivors were compared in severe COVID-19 patients, it was found that ferritin and D-dimer were good predictors of mortality, while IP-10 could not be a predictor of mortality.
- 15 July 2023
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 363-368
Open AccessInterferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease
Amaç: Makrofajlardan salınan interferon-gama indüklenebilir protein-10 (IP-10) tromboz ile ilişkilidir. Bu çalışma, şiddetli COVID-19 nedeniyle takip edilen hastaların biyokimyasal belirteçlerini ve IP-10'un mortaliteyi göstermedeki rolünü araştırmayı amaçladı. Materyal ve Metot: Bu çalışmada üniversite hastanesinin yoğun bakım ünitesinde (YBÜ) takip edilen 88 (Kadın %44,3) ağır hastanın retrospektif verileri değerlendirildi. Demografik ve laboratuvar verileri ile D-dimer, Ferritin, Ürik asit, IP-10 değerleri ve diğer biyokimyasal belirteçlere ilişkin veriler ölen ve yaşayan hastaların dosyalarından elde edildi. Bulgular: Yoğun bakımda takip edilen COVID-19 enfeksiyonlu 88 hastanın yaş ortalaması 70,5 ±10 idi. Hayatta kalan gurupta, lenfosit sayısı 1,3 (1-2,1) K/uL, ferritin 151 (90,7-255), D-dimer 386 (293,5-650), LDH 220 (185-286) iken, ölen hastalarda ise, lenfosit sayısı 0,8 (0,5-1,1), ferritin 624 (296-1254) mcg/L, D-dimer 1280 (871-2245) ug/L, LDH 429.5 (368-560) U/L saptandı. Bu parametrelerde p değeri <0,05 idi. Buna karşılık, hayatta kalmayanlarda serum IP-10 seviyeleri hayatta kalanlar da 21,3 (1,2-31,6) pg/mL iken ölen hastalarda 26,6 (11,4-43,6) pg/mL, p=0,04. Sonuç: Şiddetli COVID-19 hastalarında hayatta kalmayanlar ve hayatta kalanların karşılaştırıldığı bu çalışmada, ferritin, ve D-dimerin mortalite için iyi bir tahmin edici potansiyeli olduğu, IP-10'un ise bir belirleyici olamayacağı bulundu. Objective: Interferon-gamma inducible protein-10 (IP-10) released from macrophages is associated with thrombosis. We aimed to investigate patients' biochemical markers following severe COVID-19, concentrating on the role of IP-10 in mortality. Materials and Methods: In our study, we retrospectively evaluated data from 88 (females, 44.3%) severe patients followed in our university hospital's intensive care unit (ICU). We obtained demographic and laboratory data from our study population's files and electronic records, including D-dimer, ferritin, uric acid, IP-10 values, and other biochemical markers. Results: The mean age of all 88 patients with COVID-19 infection followed in the ICU was 70.5 ±10 years. The median for lymphocyte count was 1.3 (1-2.1) vs 0.8 (0.5-1.1) K/uL, ferritin 151 (90.7-255) vs 624 (296-1254) mcg/L, D-dimer 386 (293.5-650) vs 1280 (871-2245) ug/L, LDH 220 (185-286) vs 429.5 (368-560) U/L with a p-value of <0.05 in survivors vs non-survivors respectively. On the other hand, the level of IP-10 was 21.3 (13.2-31.6) vs 26.6 (11.4-43.6) pg/mL with a p-value of 0.04. Conclusions: In this study, in which non-survivors and survivors were compared in severe COVID-19 patients, it was found that ferritin and D-dimer were good predictors of mortality, while IP-10 could not be a predictor of mortality.
- 27 June 2023
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 18 (2) , 183-185
Gross hematuria associated with oral isotretinoin treatment in a young patient with acne vulgaris
Hematuria is defined as the presence of red blood cells in the urine and it may be observed microscopic or gross. Hematuria may originate from any site throughout the urinary tract, the glomerulus and interstitium or renal vasculature. Here, we present a 17-year-old boy who developed terminal hematuria after two months of treatment with isotretinoin for acne vulgaris. Radiological and cystoscopic assessment of the urinary system were normal. Isotretinoin treatment was stopped after dermatology consultation. In two weeks, terminal hematuria disappeared along with the dysuria, and the urine sample showed normal findings. Keywords: Acne vulgaris, adverse effect, gross hematuria, isotretinoin.
- 27 June 2023
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 18 (2) , 183-185
Gross hematuria associated with oral isotretinoin treatment in a young patient with acne vulgaris
Hematuria is defined as the presence of red blood cells in the urine and it may be observed microscopic or gross. Hematuria may originate from any site throughout the urinary tract, the glomerulus and interstitium or renal vasculature. Here, we present a 17-year-old boy who developed terminal hematuria after two months of treatment with isotretinoin for acne vulgaris. Radiological and cystoscopic assessment of the urinary system were normal. Isotretinoin treatment was stopped after dermatology consultation. In two weeks, terminal hematuria disappeared along with the dysuria, and the urine sample showed normal findings. Keywords: Acne vulgaris, adverse effect, gross hematuria, isotretinoin.
- Open Access
- 1 June 2022
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 7 (2) , 306-312
Investigation of Long-Term Follow-up Results of COVID-19 Disease in Kidney Transplant Patients and the Effect of Inactive COVID-19 Vaccine
Objective: We aimed to evaluate the long-term graft functions of kidney transplant recepients (KTR) who have been cured of the COVID-19 and to investigate the role of inactivated COVID-19 vaccine in the clinical course of the disease.Materials and Methods: KTR who had COVID-19 pneumonia between March 2020 and September 2021 were included in the study.. The clinical course of the disease was evaluated in vaccinated patients and compared with those who were not vaccinated. The laboratory information of the patients at the time of admission to the hospital, 6 months and 12 months after the disease was recorded.Results: Of the 83 patients included, 67.5% were male. COVID-19 disease developed in 20 patients after vaccination. Vaccine; it decreased the development of acute kidney injury (AKI) 5.9 fold and hospitalization in the intensive care unit (ICU) 1.4 times fold (p<0.05). In the follow-up, 10 patients died at the first admission to the hospital and no late death was recorded in the first year. Dialysis treatment was started in 5 patients due to graft loss.Conclusion: In kidney transplant patients, graft dysfunction may develop after COVID-19 infection. However, the inactivated COVID-19 vaccine; it can reduce the risks of hospitalization, AKI, and ICU admission.
- 1 June 2022
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 7 (2) , 306-312
Open AccessInvestigation of Long-Term Follow-up Results of COVID-19 Disease in Kidney Transplant Patients and the Effect of Inactive COVID-19 Vaccine
Objective: We aimed to evaluate the long-term graft functions of kidney transplant recepients (KTR) who have been cured of the COVID-19 and to investigate the role of inactivated COVID-19 vaccine in the clinical course of the disease.Materials and Methods: KTR who had COVID-19 pneumonia between March 2020 and September 2021 were included in the study.. The clinical course of the disease was evaluated in vaccinated patients and compared with those who were not vaccinated. The laboratory information of the patients at the time of admission to the hospital, 6 months and 12 months after the disease was recorded.Results: Of the 83 patients included, 67.5% were male. COVID-19 disease developed in 20 patients after vaccination. Vaccine; it decreased the development of acute kidney injury (AKI) 5.9 fold and hospitalization in the intensive care unit (ICU) 1.4 times fold (p<0.05). In the follow-up, 10 patients died at the first admission to the hospital and no late death was recorded in the first year. Dialysis treatment was started in 5 patients due to graft loss.Conclusion: In kidney transplant patients, graft dysfunction may develop after COVID-19 infection. However, the inactivated COVID-19 vaccine; it can reduce the risks of hospitalization, AKI, and ICU admission.
- 22 March 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (7) , 3176-3183
Short and mid‐term SARS‐CoV‐2 antibody response after inactivated COVID‐19 vaccine in hemodialysis and kidney transplant patients
The efficacy of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine has not been fully elucidated across the whole spectrum of patients on kidney replacement therapy. We aimed to characterize the long‐term antibody response of inactivated SARS‐CoV‐2 vaccine administered in kidney transplant recipients (KTRs) and hemodialysis (HD) patients. We performed this prospective observational study in 50 HD, 64 KTR, and 41 healthy control groups (HG) given two doses of CoronaVac. We measured anti‐Spike antibodies after 28 days of every vaccine dose, 3rd and 6th months after the first dose, and compared them between cohorts. After two doses, an anti‐spike immunoglobulin G of ≥50 AU/ml was present in HD, KTR, and HG as 44%, 7.2%, and 58.5%, respectively (p < 0.001). Furthermore, the proportion of antibody titers peaked at 86.5%, 23%, and 97.6% (p < 0.001) at the 3rd month and decreased significantly at the 6th month in most HD and HG participants, whereas this effect was not observed in KTRs from basal until the 6th month (p < 0.001). During the follow‐up, the incidence of coronavirus disease 2019 disease was higher (p < 0.003) in KTRs compared to the other groups, but there was no requirement for an intensive care unit and no death was recorded. We found a negative correlation between antibody seroconversion and age (p < 0.016). The antibody response following inactivated vaccine in dialysis patients is almost comparable to controls for 6 months. In contrast, kidney transplant patients have a poor response. These findings reinforce the need to discuss the vaccination strategy in immunocompromised patients, including the third dose with homologous or heterologous vaccines.
- 22 March 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (7) , 3176-3183
Short and mid‐term SARS‐CoV‐2 antibody response after inactivated COVID‐19 vaccine in hemodialysis and kidney transplant patients
The efficacy of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine has not been fully elucidated across the whole spectrum of patients on kidney replacement therapy. We aimed to characterize the long‐term antibody response of inactivated SARS‐CoV‐2 vaccine administered in kidney transplant recipients (KTRs) and hemodialysis (HD) patients. We performed this prospective observational study in 50 HD, 64 KTR, and 41 healthy control groups (HG) given two doses of CoronaVac. We measured anti‐Spike antibodies after 28 days of every vaccine dose, 3rd and 6th months after the first dose, and compared them between cohorts. After two doses, an anti‐spike immunoglobulin G of ≥50 AU/ml was present in HD, KTR, and HG as 44%, 7.2%, and 58.5%, respectively (p < 0.001). Furthermore, the proportion of antibody titers peaked at 86.5%, 23%, and 97.6% (p < 0.001) at the 3rd month and decreased significantly at the 6th month in most HD and HG participants, whereas this effect was not observed in KTRs from basal until the 6th month (p < 0.001). During the follow‐up, the incidence of coronavirus disease 2019 disease was higher (p < 0.003) in KTRs compared to the other groups, but there was no requirement for an intensive care unit and no death was recorded. We found a negative correlation between antibody seroconversion and age (p < 0.016). The antibody response following inactivated vaccine in dialysis patients is almost comparable to controls for 6 months. In contrast, kidney transplant patients have a poor response. These findings reinforce the need to discuss the vaccination strategy in immunocompromised patients, including the third dose with homologous or heterologous vaccines.